About Pricing FAQs Providers Trials Blog

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Impact of Intestinal Microbiota on Uremic Toxins Productions

NCT04768309·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Lead

Hospices Civils de Lyon

Age

18–80

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

Age between 18 and 80 years old
Non diabetic (fasting blood glucose \<1.26 g / L, or lack of insulin or oral antidiabetic treatment)
BMI between 18 and 30 kg / m²
Patient with CKD stage 4-5 ( eDFG \< 30 ml/min/1.73m2 CKD-EPI)
Not dialyzed
No history of kidney transplant
Patient followed in the nephrology department of Pr FOUQUE at the Lyon Sud hospital center

You may not be if

Active inflammatory, infectious, cardiovascular or neoplastic disease
Colectomy, resection of the small intestine or cholecystectomy
Patient having received antibiotics, prebiotics, probiotics in the last 3 months.
Patient using laxatives (more than 2 doses per day for the last 3 months)
Known renal pathology or known urologic malformation (healthy volunteer only)

The record

StatusCompleted

PhaseNo phase

Taking part20

StartedJun 2021

UpdatedDec 19, 2025

Conditions

Where1

Lyon Sud University Hospital
Pierre-Bénite, Rhône, France

Clareo Health | Impact of Intestinal Microbiota on Uremic Toxins Productions